Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection

G. J. Mertz, L. Eron, R. Kaufman, L. Goldberg, B. Raab, M. Conant, J. Mills, T. Kurtz, L. G. Davis, D. Baker, J. Blythe, Kenneth Fife, P. Frost, S. Horowitz, L. Gelb, J. Sperber, R. Hale, J. Herndon, L. Kaplowitz

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

In Year 1 of this two-year trial, patients with six or more genital herpes recurrences in the past year received suppressive treatment with either acyclovir, 400 mg, or placebo, orally twice daily for one year, and physician-documented recurrences were treated with open-labeled acyclovir, 200 mg, orally five times per day for five days (acute treatment). In Year 2, patients received open-labeled acyclovir treatment either with daily suppressive therapy or intermittent acute therapy. Among 683 patients who completed two years of treatment, 348 received continuous suppressive treatment for two years, 276 received acute treatment in Year 1 and suppressive treatment in Year 2, 24 received suppressive treatment in Year 1 and acute treatment in Year 2, and 35 received acute treatment for two years. Patient groups receiving intermittent acute acyclovir treatment experienced means of 7.0 to 12.6 recurrences/year during treatment as compared with 1.4 to 1.9 recurrences/year among groups receiving continuous suppressive treatment. No patients who received acute treatment remained recurrence-free for two years as compared with 29 percent of patients receiving continuous acyclovir suppression for two years. There was no evidence of cumulative toxicity detected by clinical, hematologic, or blood chemistry evaluations performed monthly in Year 1 and quarterly in Year 2. Suppressive oral acyclovir therapy remained effective and well-tolerated in this two-year trial.

Original languageEnglish (US)
Pages (from-to)14-19
Number of pages6
JournalThe American Journal of Medicine
Volume85
Issue number2 A
StatePublished - 1988
Externally publishedYes

Fingerprint

Herpes Genitalis
Acyclovir
Therapeutics
Recurrence

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. / Mertz, G. J.; Eron, L.; Kaufman, R.; Goldberg, L.; Raab, B.; Conant, M.; Mills, J.; Kurtz, T.; Davis, L. G.; Baker, D.; Blythe, J.; Fife, Kenneth; Frost, P.; Horowitz, S.; Gelb, L.; Sperber, J.; Hale, R.; Herndon, J.; Kaplowitz, L.

In: The American Journal of Medicine, Vol. 85, No. 2 A, 1988, p. 14-19.

Research output: Contribution to journalArticle

Mertz, GJ, Eron, L, Kaufman, R, Goldberg, L, Raab, B, Conant, M, Mills, J, Kurtz, T, Davis, LG, Baker, D, Blythe, J, Fife, K, Frost, P, Horowitz, S, Gelb, L, Sperber, J, Hale, R, Herndon, J & Kaplowitz, L 1988, 'Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection', The American Journal of Medicine, vol. 85, no. 2 A, pp. 14-19.
Mertz, G. J. ; Eron, L. ; Kaufman, R. ; Goldberg, L. ; Raab, B. ; Conant, M. ; Mills, J. ; Kurtz, T. ; Davis, L. G. ; Baker, D. ; Blythe, J. ; Fife, Kenneth ; Frost, P. ; Horowitz, S. ; Gelb, L. ; Sperber, J. ; Hale, R. ; Herndon, J. ; Kaplowitz, L. / Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. In: The American Journal of Medicine. 1988 ; Vol. 85, No. 2 A. pp. 14-19.
@article{b9b6151ab1914cf1893f1c977e099552,
title = "Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection",
abstract = "In Year 1 of this two-year trial, patients with six or more genital herpes recurrences in the past year received suppressive treatment with either acyclovir, 400 mg, or placebo, orally twice daily for one year, and physician-documented recurrences were treated with open-labeled acyclovir, 200 mg, orally five times per day for five days (acute treatment). In Year 2, patients received open-labeled acyclovir treatment either with daily suppressive therapy or intermittent acute therapy. Among 683 patients who completed two years of treatment, 348 received continuous suppressive treatment for two years, 276 received acute treatment in Year 1 and suppressive treatment in Year 2, 24 received suppressive treatment in Year 1 and acute treatment in Year 2, and 35 received acute treatment for two years. Patient groups receiving intermittent acute acyclovir treatment experienced means of 7.0 to 12.6 recurrences/year during treatment as compared with 1.4 to 1.9 recurrences/year among groups receiving continuous suppressive treatment. No patients who received acute treatment remained recurrence-free for two years as compared with 29 percent of patients receiving continuous acyclovir suppression for two years. There was no evidence of cumulative toxicity detected by clinical, hematologic, or blood chemistry evaluations performed monthly in Year 1 and quarterly in Year 2. Suppressive oral acyclovir therapy remained effective and well-tolerated in this two-year trial.",
author = "Mertz, {G. J.} and L. Eron and R. Kaufman and L. Goldberg and B. Raab and M. Conant and J. Mills and T. Kurtz and Davis, {L. G.} and D. Baker and J. Blythe and Kenneth Fife and P. Frost and S. Horowitz and L. Gelb and J. Sperber and R. Hale and J. Herndon and L. Kaplowitz",
year = "1988",
language = "English (US)",
volume = "85",
pages = "14--19",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "2 A",

}

TY - JOUR

T1 - Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection

AU - Mertz, G. J.

AU - Eron, L.

AU - Kaufman, R.

AU - Goldberg, L.

AU - Raab, B.

AU - Conant, M.

AU - Mills, J.

AU - Kurtz, T.

AU - Davis, L. G.

AU - Baker, D.

AU - Blythe, J.

AU - Fife, Kenneth

AU - Frost, P.

AU - Horowitz, S.

AU - Gelb, L.

AU - Sperber, J.

AU - Hale, R.

AU - Herndon, J.

AU - Kaplowitz, L.

PY - 1988

Y1 - 1988

N2 - In Year 1 of this two-year trial, patients with six or more genital herpes recurrences in the past year received suppressive treatment with either acyclovir, 400 mg, or placebo, orally twice daily for one year, and physician-documented recurrences were treated with open-labeled acyclovir, 200 mg, orally five times per day for five days (acute treatment). In Year 2, patients received open-labeled acyclovir treatment either with daily suppressive therapy or intermittent acute therapy. Among 683 patients who completed two years of treatment, 348 received continuous suppressive treatment for two years, 276 received acute treatment in Year 1 and suppressive treatment in Year 2, 24 received suppressive treatment in Year 1 and acute treatment in Year 2, and 35 received acute treatment for two years. Patient groups receiving intermittent acute acyclovir treatment experienced means of 7.0 to 12.6 recurrences/year during treatment as compared with 1.4 to 1.9 recurrences/year among groups receiving continuous suppressive treatment. No patients who received acute treatment remained recurrence-free for two years as compared with 29 percent of patients receiving continuous acyclovir suppression for two years. There was no evidence of cumulative toxicity detected by clinical, hematologic, or blood chemistry evaluations performed monthly in Year 1 and quarterly in Year 2. Suppressive oral acyclovir therapy remained effective and well-tolerated in this two-year trial.

AB - In Year 1 of this two-year trial, patients with six or more genital herpes recurrences in the past year received suppressive treatment with either acyclovir, 400 mg, or placebo, orally twice daily for one year, and physician-documented recurrences were treated with open-labeled acyclovir, 200 mg, orally five times per day for five days (acute treatment). In Year 2, patients received open-labeled acyclovir treatment either with daily suppressive therapy or intermittent acute therapy. Among 683 patients who completed two years of treatment, 348 received continuous suppressive treatment for two years, 276 received acute treatment in Year 1 and suppressive treatment in Year 2, 24 received suppressive treatment in Year 1 and acute treatment in Year 2, and 35 received acute treatment for two years. Patient groups receiving intermittent acute acyclovir treatment experienced means of 7.0 to 12.6 recurrences/year during treatment as compared with 1.4 to 1.9 recurrences/year among groups receiving continuous suppressive treatment. No patients who received acute treatment remained recurrence-free for two years as compared with 29 percent of patients receiving continuous acyclovir suppression for two years. There was no evidence of cumulative toxicity detected by clinical, hematologic, or blood chemistry evaluations performed monthly in Year 1 and quarterly in Year 2. Suppressive oral acyclovir therapy remained effective and well-tolerated in this two-year trial.

UR - http://www.scopus.com/inward/record.url?scp=0023767079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023767079&partnerID=8YFLogxK

M3 - Article

C2 - 3044076

AN - SCOPUS:0023767079

VL - 85

SP - 14

EP - 19

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 2 A

ER -